Gil Blum

Gil Blum, PhD is a Senior Biotech Analyst at Needham & Company, specializing in the coverage of biotech companies with a focus on gene therapy, having previously served as a Biotech Analyst. Prior to this role, Gil was a Scientific Advisor at Cadwalader, Wickersham & Taft LLP, where responsibilities included IP due diligence for pharmaceutical products and generating patentability opinions. A Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center, Gil collaborated with Takeda Pharmaceuticals on histone methyl transferase inhibitors. Early in the career, extensive research was conducted as a Graduate Student at Weill Cornell Medicine, specializing in histone methyl transferases. Previous experience includes a Patent Trainee role at Blum, Gador & Co. and serving as a Material Engineer and team leader in the Israel Defense Forces' elite R&D unit. Educational qualifications include a PhD in Chemical Biology from both Joan & Sanford I. Weill Medical College of Cornell University and Weill Cornell Graduate School of Medical Sciences, alongside a Bachelor's degree in Chemistry from Tel Aviv University and a Financial Accounting certification from The Wharton School.